News

Brenner devoted his career to conducting groundbreaking basic research. His many contributions to molecular biology led to his being co-awarded the Nobel Prize in Physiology or Medicine in 2002.

In a study with the National Institute on Drug Abuse, scientists at Scripps Research discovered that oxytocin blocked enhanced drinking in alcohol-dependent rats, concluding that targeting the oxytocin system may be a successful pharmaceutical approach for treating alcohol-use disorder.

Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a progressive and often fatal disease.

New research will now make it possible to screen drug candidates more reliably and investigate the root cause of Parkinson’s disease.

Charity Navigator awards Scripps Research four stars for exceeding industry standards in financial health, accountability and transparency.

Scientists find evidence that RNA and DNA could have arisen from the same set of precursor molecules before life evolved four billion years ago.

Currently there is no treatment for myotonic dystrophy type 1. Now, researchers say they have made a potential drug that targets a disease-causing RNA at the root of the disease.  

The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial to test a novel HIV vaccine candidate, an advance in vaccine design enabled by Scripps Research discoveries.

New method could enable faster study of strategies to combat age-related diseases.

New drugs for neurodegenerative and genetic disorders making their way to the marketplace.

Scientists at Scripps Research have found that they can reverse the desire to drink in alcohol-dependent rats—with the flip of a switch.

New book Deep Medicine released and garners significant media attention. Click to read more and review ongoing media coverage. 

In a breakthrough with applicability across many flu strains, researchers find a potential small molecule that mimics antibodies to treat disease.

For the last decade researchers have been developing a drug candidate that eases inflammation and protects brain cells from damage. Now, research shows another potential application: treating Alzheimer’s disease. 

In a New York Times op-ed, Eric Topol, MD, founder and director of Scripps Research Translational Institute, discusses the science of nutrition and the need for diet to be individualized.

Scripps Research assistant professor Luke Lairson, PhD, and colleagues have discovered a compound that potently and selectively kills the stem-like cells that make glioblastoma brain cancers so deadly.

Program supports workforce training recommended by Eric Topol, MD, in an independent review of the digital future of the National Health Service.

Inspired by electric car batteries, researchers developed a battery-like system that allows them to make potential advancements for the manufacturing of medicines.

Scripps Research professor Ramanarayanan Krishnamurthy, PhD, has been named co-leader of a new NASA initiative to investigate how life emerged from Earth’s early environments.

Cells removed from patients’ bloodstreams and genetically altered may allow more effective vaccines for HIV, influenza, hepatitis.

Neuroscientists Giordano Lippi and Li Ye have received grants from the Whitehall Foundation to support their studies into brain function.

For breast cancer patients with dwindling options, switching on HER2 sensitivity might be life-changing. Disney’s group described shifting three different cancer cell lines from HER2-negative status to HER2-positive status with the addition of a selective micro-RNA binding molecule.

Synapse instability may underlie many neurodegenerative diseases, including Alzheimer’s. A new study from the lab of Brock Grill, PhD, sheds light on synapse maintenance.  

Chemistry Professor Matthew D. Disney, PhD, of Scripps Research in Jupiter, Florida, has been awarded the Raymond and Beverly Sackler International Prize in Chemistry from Tel Aviv University.